Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

UBR5 is co-amplified with MYC in breast tumors and encodes an ubiquitin ligase that limits MYC-dependent apoptosis.

Qiao X, Liu Y, Llamazares Prada M, Mohan AK, Gupta A, Jaiswal A, Sharma M, Merisaari J, Haikala HM, Talvinen K, Yetukuri L, Pylvänäinen JW, Klefström J, Kronqvist P, Meinander A, Aittokallio T, Hietakangas V, Eilers M, Westermarck J.

Cancer Res. 2020 Feb 6. pii: canres.1647.2019. doi: 10.1158/0008-5472.CAN-19-1647. [Epub ahead of print]

PMID:
32029551
2.

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J.

Nat Commun. 2019 Feb 20;10(1):932. doi: 10.1038/s41467-019-08956-x.

3.

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schüler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkilä P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefström J.

Nat Commun. 2019 Feb 6;10(1):620. doi: 10.1038/s41467-019-08541-2. Erratum in: Nat Commun. 2019 Feb 20;10(1):932.

4.

Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.

Damalanka VC, Han Z, Karmakar P, O'Donoghue AJ, La Greca F, Kim T, Pant SM, Helander J, Klefström J, Craik CS, Janetka JW.

J Med Chem. 2019 Jan 24;62(2):480-490. doi: 10.1021/acs.jmedchem.8b01536. Epub 2019 Jan 4.

PMID:
30571119
5.

Design, Synthesis, and Testing of Potent, Selective Hepsin Inhibitors via Application of an Automated Closed-Loop Optimization Platform.

Pant SM, Mukonoweshuro A, Desai B, Ramjee MK, Selway CN, Tarver GJ, Wright AG, Birchall K, Chapman TM, Tervonen TA, Klefström J.

J Med Chem. 2018 May 24;61(10):4335-4347. doi: 10.1021/acs.jmedchem.7b01698. Epub 2018 May 14.

PMID:
29701962
6.

Phenotype-driven identification of epithelial signalling clusters.

Marques E, Peltola T, Kaski S, Klefström J.

Sci Rep. 2018 Mar 5;8(1):4034. doi: 10.1038/s41598-018-22293-x.

7.

Analyzing the Type II Transmembrane Serine Protease Hepsin-Dependent Basement Membrane Remodeling in 3D Cell Culture.

Pant SM, Belitskin D, Ala-Hongisto H, Klefström J, Tervonen TA.

Methods Mol Biol. 2018;1731:169-178. doi: 10.1007/978-1-4939-7595-2_16.

PMID:
29318553
8.

MYC and AMPK-Save Energy or Die!

Haikala HM, Anttila JM, Klefström J.

Front Cell Dev Biol. 2017 Apr 11;5:38. doi: 10.3389/fcell.2017.00038. eCollection 2017. Review.

9.

Myc requires RhoA/SRF to reprogram glutamine metabolism.

Haikala HM, Marques E, Turunen M, Klefström J.

Small GTPases. 2018 May 4;9(3):274-282. doi: 10.1080/21541248.2016.1224287. Epub 2016 Sep 20.

10.

Data integration to prioritize drugs using genomics and curated data.

Louhimo R, Laakso M, Belitskin D, Klefström J, Lehtonen R, Hautaniemi S.

BioData Min. 2016 May 26;9:21. doi: 10.1186/s13040-016-0097-1. eCollection 2016.

11.

MYC-induced apoptosis in mammary epithelial cells is associated with repression of lineage-specific gene signatures.

Haikala HM, Klefström J, Eilers M, Wiese KE.

Cell Cycle. 2016;15(3):316-23. doi: 10.1080/15384101.2015.1121351.

12.

Par6 family proteins in cancer.

Marques E, Klefström J.

Oncoscience. 2015 Oct 7;2(11):894-5. eCollection 2015. No abstract available.

13.

Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation.

Myant K, Qiao X, Halonen T, Come C, Laine A, Janghorban M, Partanen JI, Cassidy J, Ogg EL, Cammareri P, Laiterä T, Okkeri J, Klefström J, Sears RC, Sansom OJ, Westermarck J.

Cell Rep. 2015 Aug 11;12(6):1019-31. doi: 10.1016/j.celrep.2015.07.003. Epub 2015 Jul 30.

14.

Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

Tervonen TA, Belitškin D, Pant SM, Englund JI, Marques E, Ala-Hongisto H, Nevalaita L, Sihto H, Heikkilä P, Leidenius M, Hewitson K, Ramachandra M, Moilanen A, Joensuu H, Kovanen PE, Poso A, Klefström J.

Oncogene. 2016 Apr 7;35(14):1832-46. doi: 10.1038/onc.2015.248. Epub 2015 Jul 13.

PMID:
26165838
15.

Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers.

Marques E, Englund JI, Tervonen TA, Virkunen E, Laakso M, Myllynen M, Mäkelä A, Ahvenainen M, Lepikhova T, Monni O, Hautaniemi S, Klefström J.

Oncogene. 2016 Mar 17;35(11):1386-98. doi: 10.1038/onc.2015.196. Epub 2015 Jun 15.

16.

Repression of SRF target genes is critical for Myc-dependent apoptosis of epithelial cells.

Wiese KE, Haikala HM, von Eyss B, Wolf E, Esnault C, Rosenwald A, Treisman R, Klefström J, Eilers M.

EMBO J. 2015 Jun 3;34(11):1554-71. doi: 10.15252/embj.201490467. Epub 2015 Apr 20.

17.

Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2.

Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jücker M, Eils R, Fehm T, Trumpp A, Johnsen SA, Klefström J, Wilmanns M, Müller V, Pantel K, Wikman H.

Cancer Discov. 2015 May;5(5):506-19. doi: 10.1158/2159-8290.CD-14-1042. Epub 2015 Feb 25.

18.

Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo.

Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, van der Kuip H; IMI PREDECT Consortium.

Biotechnol J. 2014 Sep;9(9):1115-28. doi: 10.1002/biot.201300492. Review.

PMID:
25174503
19.

Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.

Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefström J, Aittokallio T, Weiss C, Ristimäki A, Visakorpi T, Westermarck J.

Cancer Res. 2013 Nov 15;73(22):6757-69. doi: 10.1158/0008-5472.CAN-13-1002. Epub 2013 Sep 26.

20.

Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4.

Partanen JI, Tervonen TA, Klefström J.

Philos Trans R Soc Lond B Biol Sci. 2013 Sep 23;368(1629):20130111. doi: 10.1098/rstb.2013.0111. Print 2013. Review.

Supplemental Content

Loading ...
Support Center